Search

Objectives: To estimate notification rates for infectious syphilis in women of reproductive age and congenital syphilis in Australia. Study design: Retrospective cohort study; analysis of national infectious syphilis and enhanced congenital syphilis surveillance data. Setting, participants: Women aged 15–44 years diagnosed with infectious syphilis, and babies with congenital syphilis, Australia, 2011–2021. Main outcome measures: Numbers and rates of infectious syphilis notifications, by Indigenous status and age group; numbers and rates of congenital syphilis, by Indigenous status of the infant; antenatal care history for mothers of infants born with congenital syphilis. Results: During 2011–2021, 5011 cases of infectious syphilis in women aged 15–44 years were notified. The notification rate for Aboriginal and Torres Strait Islander women rose from 56 (95% confidence interval [CI], 45–65) cases per 100 000 in 2011 to 227 (95% CI, 206–248) cases per 100 000 population in 2021; for non‐Indigenous women, it rose from 1.1 (95% CI, 0.8–1.4) to 9.2 (95% CI, 8.4–10.1) cases per 100 000 population. The notification rate was higher for Aboriginal and Torres Strait Islander women than for non‐Indigenous women (incidence rate ratio [IRR], 23.1; 95% CI, 19.7–27.1), lower for 15–24‐ (IRR, 0.7; 95% CI, 0.6–0.9) and 35–44‐year‐old women (IRR, 0.6; 95% CI, 0.5–0.7) than for 25–34‐year‐old women, and higher in remote regions than in major cities (IRR, 2.7; 95% CI, 2.2–3.8). During 2011–2021, 74 cases of congenital syphilis were notified, the annual number increasing from six in 2011 to a peak of 17 in 2020; the rate was consistently higher among Aboriginal and Torres Strait Islander infants than among non‐Indigenous infants (2021: 38.3 v 2.1 per 100 000 live births). The mothers of 32 infants with congenital syphilis (43%) had not received antenatal care. Conclusions: The number of infectious syphilis notifications for women of reproductive age increased in Australia during 2011–2021, as did the number of cases of congenital syphilis. To avert congenital syphilis, antenatal screening of pregnant women, followed by prompt treatment for infectious syphilis when diagnosed, needs to be improved. [ABSTRACT FROM AUTHOR]

Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of hepatitis C virus (HCV) infection. This study assessed the effectiveness of direct‐acting antiviral (DAA) therapy among Aboriginal peoples in the three years following universal access in Australia. REACH‐C, a national multicentre prospective cohort study, evaluated HCV treatment outcomes from sequential DAA initiations across 33 health services between March 2016 and June 2019. DAA effectiveness was assessed by sustained virological response (SVR) in the total (full analysis set) and effectiveness (modified analysis set excluding those lost to follow‐up) populations. Overall, 915 (10%) Aboriginal and 8095 (90%) non‐Indigenous people commenced DAA therapy, of whom 30% and 16% reported current injecting drug use and 73% and 42% were treated in primary care, respectively. SVR in the total and effectiveness populations was 74% and 94% among Aboriginal people and 82% and 94% among non‐Indigenous people, with loss to follow‐up contributing to lower SVR in the total population analysis (22% Aboriginal, 13% non‐Indigenous). Among Aboriginal people, returning for follow‐up was positively associated with older age (aOR 1.20; 95% CI 1.04, 1.39) and SVR was negatively associated with cirrhosis (aOR 0.39; 95% CI 0.19, 0.80) and prior DAA treatment (aOR 0.14; 95% CI 0.04, 0.49). Factors reflecting higher vulnerability or inequity were not associated with returning for testing or SVR. DAA therapy was highly effective among Aboriginal peoples with HCV treated through primary and tertiary services. Tailored community‐led interventions are necessary to optimize follow‐up and engagement. Sustained DAA uptake and equitable access to care, treatment and prevention are required for HCV elimination. [ABSTRACT FROM AUTHOR]

Introduction Methods Results Discussion and Conclusions Evaluating progress towards hepatitis C virus (HCV) elimination among Aboriginal and Torres Strait Islander peoples is critical given the disproportionate burden of infection. We examined factors associated with current HCV infection and self‐reported treatment among Aboriginal and Torres Strait Islander (hereafter referred to as Aboriginal peoples) and non‐Aboriginal peoples who inject drugs (PWID) in Australia.ETHOS Engage is an observational cohort study of PWID attending drug treatment and needle and syringe programs in Australia. Participants underwent point‐of‐care HCV RNA testing (Xpert HCV RNA Viral Load Fingerstick) and completed a questionnaire including self‐reported history of HCV treatment.Between May 2018 and June 2021, 2395 participants were enrolled and 555 (23%) identified as Aboriginal (median age 42 years, 58% were men, 63% injected drugs in last month, 76% ever incarcerated). HCV RNA prevalence was 23% among Aboriginal PWID (24% in 2018–2019 and 21% in 2019–2021; p = 0.44), and 21% among non‐Aboriginal PWID (24% in 2018–2019 and 16% in 2019–2021; p < 0.001). Self‐reported HCV treatment was 65% among Aboriginal PWID (63% in 2018–2019 and 69% in 2019–2021; p = 0.30), and 70% among non‐Aboriginal PWID (67% in 2018–2019 and 75% in 2019–2021; p < 0.001). Among Aboriginal PWID, current HCV infection was associated with recently injecting drugs and receiving opioid agonist treatment, and self‐reported HCV treatment was negatively associated with younger age, homelessness and recently injecting drugs.Equitable access to HCV care and prevention is needed to ensure Australia meets its elimination targets among Aboriginal PWID. [ABSTRACT FROM AUTHOR]